
Lars Tanum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10610615/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence. JAMA Psychiatry, 2017, 74, 1197.	11.0	200
2	Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. Journal of Pain Research, 2017, Volume 10, 515-525.	2.0	164
3	Neuropsychological functioning in late-life depression. Frontiers in Psychology, 2013, 4, 381.	2.1	45
4	Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone. JAMA Psychiatry, 2019, 76, 127.	11.0	44
5	Clinical efficacy of formula-based bifrontal versus right unilateral electroconvulsive therapy (ECT) in the treatment of major depression among elderly patients: A pragmatic, randomized, assessor-blinded, controlled trial. Journal of Affective Disorders, 2015, 175, 8-17.	4.1	40
6	The Role of Baseline Cognitive Function in the Neurocognitive Effects of Electroconvulsive Therapy in Depressed Elderly Patients. Clinical Neuropsychologist, 2015, 29, 487-508.	2.3	21
7	Effectiveness, safety and feasibility of extendedâ€release naltrexone for opioid dependence: a 9â€month followâ€up to a 3â€month randomized trial. Addiction, 2018, 113, 1840-1849.	3.3	20
8	Tapering from Methadone or Buprenorphine during Pregnancy: Maternal and Neonatal Outcomes in Norway 1996-2009. European Addiction Research, 2015, 21, 253-261.	2.4	19
9	Cognitive Effects of Bifrontal Versus Right Unilateral Electroconvulsive Therapy in the Treatment of Major Depression in Elderly Patients. Journal of ECT, 2016, 32, 151-158.	0.6	18
10	Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). BMC Pharmacology & Toxicology, 2016, 17, 18.	2.4	18
11	Systematic analysis of the cerebrospinal fluid proteome of fibromyalgia patients. Journal of Proteomics, 2019, 190, 35-43.	2.4	17
12	No increased pain among opioidâ€dependent individuals treated with extendedâ€release naltrexone or buprenorphineâ€naloxone: A 3â€month randomized study and 9â€month openâ€treatment followâ€up study. American Journal on Addictions, 2019, 28, 77-85.	1.4	16
13	Baseline cognitive function does not predict the treatment outcome of electroconvulsive therapy (ECT) in late-life depression. Journal of Affective Disorders, 2015, 185, 67-75.	4.1	13
14	Speed of recovery from disorientation may predict the treatment outcome of electroconvulsive therapy (ECT) in elderly patients with major depression. Journal of Affective Disorders, 2016, 190, 178-186.	4.1	11
15	Discrepancy in Ratings of Shared Decision Making Between Patients and Health Professionals: A Cross Sectional Study in Mental Health Care. Frontiers in Psychology, 2020, 11, 443.	2.1	9
16	<p>CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia</p> . Journal of Pain Research, 2019, Volume 12, 2875-2889.	2.0	8
17	Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. European Addiction Research, 2019, 25, 303-309.	2.4	7
18	Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone. Journal of Clinical Medicine, 2021, 10, 4558.	2.4	7

LARS TANUM

#	Article	IF	CITATIONS
19	â€~Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study. Journal of Substance Abuse Treatment, 2021, , 108667.	2.8	7
20	Adapting treatment length to opioidâ€dependent individuals' needs and preferences: a 2â€year followâ€up to a 1â€year study of extendedâ€release naltrexone. Addiction, 2021, 116, 2084.	3.3	5
21	The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse. European Addiction Research, 2022, 28, 56-67.	2.4	3
22	The effect of mianserin in chronic idiopathic abdominal pain A pilot study. Nordic Journal of Psychiatry, 1993, 47, 351-354.	1.3	2
23	Risk of Relapse Among Opioidâ€Dependent Patients Treated With Extendedâ€Release Naltrexone or Buprenorphineâ€Naloxone: A Randomized Clinical Trial. American Journal on Addictions, 2021, 30, 453-460.	1.4	2
24	Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up. Journal of Substance Abuse Treatment, 2022, 135, 108656.	2.8	1